Does mammary ductoscopy have a role in clinical practice? by Al Sarakbi, W et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
International Seminars in Surgical 
Oncology
Open Access Research
Does mammary ductoscopy have a role in clinical practice?
W Al Sarakbi1, M Salhab1 and K Mokbel*1,2
Address: 1The Breast Care Centre, St. George's & The Princess Grace Hospitals, London, UK and 2Consultant Breast & Endocrine Surgeon, St. 
George's Hospital, Blackshaw Rd, London SW17 0QT, UK
Email: W Al Sarakbi - walsarakbi@hotmail.com; M Salhab - msalhab1@excite.com; K Mokbel* - kefahmokbel@hotmail.com
* Corresponding author    
Abstract
Background: Mammary ductoscopy (MD) is a newly developed endoscopic technique that allows direct visualisation of the
mammary ductal epithelium using sub-millimetre fiberoptic microendoscopes inserted through the ductal opening onto the
nipple surface. These scopes also provide working channels for insufflation, irrigation, ductal lavage, and possible therapeutic
intervention. MD can be performed under local anaesthesia in the office setting.
The objective of this study is to assess the technical feasibility of mammary ductoscopy, and examine its role in guiding ductal
excision surgery and the early diagnosis of malignancy.
Methods: Mammary ductoscopy (MD) was performed using a 1 mm fiberoptic microendoscope (Mastascope TM) in 26 patients
(age range: 14–73 years): 13 patients undergoing mastectomy (n = 12) or lumpectomy (n = 1) for ductal carcinoma (including
12 cases of DCIS and one case of infiltrating ductal carcinoma) and 13 patients with pathological nipple discharge (PND) and
benign breast imaging and simple discharge cytology. Of the latter group: 10 procedures were performed under local anaesthesia
(LA) in the office setting and 3 procedures were carried out under general anaesthesia (GA) to guide duct excision surgery. The
ductoscopic appearances in this group were graded between 0 and 5 (D0–D5) according to the degree of suspicion.
Results: Intraoperative MD was accomplished in 11 (84.6%) of 13 patients undergoing surgery for DCIS. MD was unsuccessful
in 2 cases: one patient (aged 73 years) had sclerosis of the nipple and one patient had preoperative vital blue injection in the
subareolar region as part of the sentinel node biopsy thus resulting in inadequate visualisation. Intraductal pathology was
visualised in 8 (80%) of the 10 cases undergoing mastectomy but ductoscopic cytology was positive for malignancy in only 2 cases
(sensitivity = 16%, specificity = 100%). In the office setting, MD was accomplished in 9 (90%) out of 10 patients with PND and
was well tolerated (mean pain score = 3.8 out of 10: range 0–7). Of these 10 patients; MD was inadequate (D0) in one patient
due to complete occlusion of lumen by the lesion, showed a papilloma in 3 patients (D3), duct ectasia (D2) in 3 patients, irregular
thickening of the lumen suspicious of DCIS (D4) in one patient and non-specific benign findings (D2) in 2 patients. Three women
with benign ductoscopy and ductoscopy-assisted cytology were reassured and treated conservatively. The remaining 7 patients
had ductoscopy-guided duct excision which revealed DCIS in one, papilloma in 4 and benign breast disease in 2 patients.
Adequate cellular yield was obtained in 7(70%) out of 10 cases (benign cytology). The three patients who had MD under GA
during microdochectomy had benign endoscopic appearances and final histology (one papilloma and 2 cases of duct ectasia).
Conclusion: MD is technically feasible in most patients and has a potential in the early detection of breast cancer. The
procedure can be performed safely in the office setting and should be considered in all patients presenting with a single duct
PND. MD has the potential to reduce the number of duct excision procedures and minimise the extent of surgical resection.
Ductoscopic cytology is not sufficiently sensitive for the diagnosis of malignancy and the development of a biopsy tool that
obtains tissue under direct visualisation is required.
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Background
Mammary ductoscopy (MD) is a new endoscopic tech-
nique that has been evolving over the last 15 years [1-3].
The initial scopes were of a large calibre with limited
optics and lacked any working channels thus leading to a
poor image quality [4]. Furthermore the images generated
by the earlier scopes were too small and imprecise for
accurate clinical judgement. Recent technological
advances in endoscopic techniques, however, have over-
come many of these obstacles. The current generation of
microendoscopes (rigid or flexible) use excellent fibreop-
tics and measure between 0.7 mm and 1.2 mm in external
diameter [2] (Figure 1). Inserted through the ductal open-
ing on the nipple surface, they allow direct visualization
of the mammary ductal epithelium where most benign
and malignant pathologies originate [2,5]. These scopes
also provide working channels for insufflation, irrigation,
ductal lavage, and possible therapeutic intervention [2].
The sharp clear magnified images (Figure 2) viewed on a
video monitor combined with the use of intraductal
biopsy devices such as micro-brushes and other biopsy
tools allow the retrieval of tissue specimens under direct
visualisation for cytopathological analysis [2,5,6]. MD
can be performed under local anaesthesia in the office set-
ting with minimal discomfort and no reported complica-
tions [2].
The potential clinical applications of MD include the
management of women with pathological nipple dis-
charge, guiding of breast conserving surgery for cancer,
and screening of high risk women [5,7-11].
PND is a relatively common symptom accounting for
approximately 5% of all women attending symptomatic
breast clinics [12]. Papilloma is the commonest patholog-
A breast ductoscope with a 1 mm external diameter and a 0.45 mm working channel Figure 1
A breast ductoscope with a 1 mm external diameter and a 0.45 mm working channel.International Seminars in Surgical Oncology 2006, 3:16 http://www.issoonline.com/content/3/1/16
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ical finding in women with PND accounting for 40% to
70% of cases followed by adenomatous or papillary epi-
thelial proliferations (14%) [12,13]. However the inci-
dence of malignancy (invasive or in situ) as a cause of
PND varies between 1 and 23% depending upon the
series studied [12]. The most reliable approach to both
establish the diagnosis and control the discharge is ductal
excision, the success of which is dependant on identifying
the correct origin of the discharge. When a specific duct
cannot be identified then blind excision of the retroareo-
lar ductal system is usually performed.
Ductography is the traditional diagnostic technique used
for investigating PND. Unlike ductography, ductoscopy
can detect lesions that do not completely obstruct the duc-
tal lumen. Furthermore, MD can detect multiple lesions
within the same duct. It also plays an important role in
guiding and minimising surgical duct excision as it offers
accurate localization of the lesion, and can negate the
need for surgery if the PND was proven to be benign on
both endoscopy and biopsy [2]. Other advantages of MD
include ductal lavage under direct visualization, and intra-
operative guidance especially for lesions deep within the
ductal system [10]. In addition to visualising intraductal
lesions, cytological analysis of endoscopically retrieved
ductal lavage has been recently reported to be more accu-
rate than simple discharge cytology [1,3,12,14].
This study is part of an ongoing long-term research project
aimed at exploring the potential clinical applications of
MD.
Patients and methods
MD was performed on a group of 26 patients (Age range:
14 – 73) after obtaining an informed consent.
We used a 1 mm fiberoptic microendoscope (Masta-
scope™). The endoscope was inserted through the ductal
opening on the nipple surface after dilating the relevant
duct with a suitable probe (Bowmann's lacrimal dilators).
Saline solution or sterile water was injected into the duct
through the working channel (0.45 mm) in order to
widen it and facilitate the passage of the endoscope for
clear visualisation of the intraductal space. The optical
viewing and endoscopic system magnifies breast tissue up
to 60 times its actual size and allows the identification of
breast lesions up to 1/100th the size of those detected with
conventional mammography and magnetic resonance
imaging (MRI). Distance of ductoscopic navigation
ranged between 0 – 10 cm. The procedure can be per-
formed under local anaesthesia (topical local anaesthetic
cream plus intradermal local anaesthetic injection at the
areolar margin) in the office setting [1,2,5].
Mammary ductoscopy images: (A) Normal mammary ducts,  (B) Intraductal papilloma (C) DCIS Figure 2
Mammary ductoscopy images: (A) Normal mammary ducts, 
(B) Intraductal papilloma (C) DCIS.
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MD was performed on a total of 26 patients divided into
the following subgroups:
Group (A) consists of 13 patients undergoing mastectomy
(n = 12) or lumpectomy (n = 1) for ductal carcinoma
(including 12 cases of DCIS and one case of infiltrating
ductal carcinoma). This group underwent intraoperative
MD under general anaesthetic (GA) to assess the intraduc-
tal pathology. The tumour-bearing quadrant was mas-
saged until nipple discharge was obtained for index duct
identification.
Group (B) consists of 13 patients presenting with PND.
Conventional investigations including mammography
and/or ultrasound and simple discharge cytology were
negative for malignancy. 10 of these patients underwent
MD in the office setting to assess the cause and the pres-
ence of any suspicious pathology, and 3 patients under-
went MD under (GA) to guide duct excision surgery.
Mamoscopic views of cancerous tissue included irregular
thickening of the lumen, ulcerating proliferation, cross-
bridging structures, extrinsic compression of ducts, and
irregular polypoid masses. Both papillomas and duct ecta-
sia had more characteristic and therefore typically diag-
nostic appearances (Figure 2). Papillomas appeared as
smooth well-defined outgrowth, while duct ectasia
appeared as dilated ducts with small solid white debris.
These findings were confirmed by the subsequent histo-
logical analysis. The predictive value of these views is yet
to be validated in large multi-centre prospective trials.
We proposed a new scoring system to describe ductos-
copic appearances. According to this system the ductos-
copic appearances were graded between 0 and 5 (D0–D5)
according to the degree of suspicion (Table 1). This system
complements but does not substitute the final histological
validation.
Results
Intraoperative MD was accomplished in 11 out of 13
patients in group A (84.6%). MD was unsuccessful in 2
cases: one patient (aged 73 years) had sclerosis of the nip-
ple and one patient had preoperative vital blue injection
in the subareolar region as part of the sentinel node
biopsy thus resulting in inadequate visualisation. Intra-
ductal pathology was visualised in 8 (80%) of the 10 cases
undergoing mastectomy but ductoscopic cytology was
positive for malignancy in only 2 cases (sensitivity = 16%,
specificity = 100%). In the single case of lumpectomy, the
patient presented with a single nipple discharge. Mam-
mography, ultrasound and simple discharge cytology
showed no evidence of malignancy. Ductography
revealed an intraductal papilloma. Initially, MD was per-
formed under local anaesthetic (LA) and showed exten-
sive epithelial proliferation suggestive of DCIS 5 cm from
the nipple. MD guided excision showed low grade DCIS
(clear margins). MD showed an intraductal papilloma in
3 patients' non-specific benign changes in one patient.
Subsequent ductoscopy-assisted duct excision confirmed
these endoscopic findings.
In the office setting MD was accomplished in 9 (90%) out
of 10 patients with PND and was well tolerated (mean
pain score = 3.8 out of 10: range 0–7). Of these 10
patients; MD was inadequate (D0) in one patient (due to
complete occlusion of lumen by the lesion), showed a
papilloma in 3 patients (D3), duct ectasia (D2) in 3
patients, irregular thickening of the lumen suspicious of
DCIS (D4) in one patient and non-specific benign find-
ings (D2) in 2 patients. Three women with benign ductos-
copy and ductoscopy-assisted cytology were reassured and
treated conservatively. The remaining 7 patients had duc-
toscopy-guided duct excision which revealed DCIS in one,
papilloma in 4 and benign breast disease in 2 patients.
Adequate cellular yield was obtained in 7 (70%) out of 10
cases and interpreted as benign. Table 2 illustrates the cor-
relation between ductoscopy appearances and post-oper-
ative histology in patients who underwent surgery, and
cytology in patients' who were treated conservatively.
MD was also used to guide duct excision in the 3 patients
undergoing surgery for PND under GA. All the three
patients had benign endoscopic appearances and final
histology (one papilloma and 2 cases of duct ectasia).
Although ductoscopic lavage cytology (Figure 3) revealed
malignant cells in some cases of DCIS, overall it had a low
cellular yield and lacked sensitivity (16%).
Table 1: Proposed scoring system for ductoscopic appearances (Mokbel's classification system)
D0 Inadequate views/unsuccessful procedure
D1 Normal mammary ducts
D2 Typically benign appearance
D3 Low index of suspicion/indeterminate most likely benign
D4 Appearances suspicious of malignancy
D5 Appearances suspicious of malignancy plus positive ductscopic cytologyInternational Seminars in Surgical Oncology 2006, 3:16 http://www.issoonline.com/content/3/1/16
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Discussion
MD can be performed safely in the office setting and
should be considered in all patients presenting with a sin-
gle duct PND. The technique has the potential to reduce
the number of duct excision procedures and minimise the
extent of surgical resection. Simple light transillumination
through the skin during MD can be used to guide duct
excision. We have recently described a new technique
Table 2: Findings in patients undergoing MD in the office setting for pathological nipple discharge.
Patients Appearance Classification Histology
1 (10%) Inadequate D0 Papilloma
3 (30%) Papilloma D3 3 Papilloma
3 (30%) Duct ectasia D2 None (conservative management) 
benign cytology
1 (10%) DCIS D4 DCIS
2 (20%) Non-specific benign D2 Benign breast disease
Ductoscopic cytology showing DCIS Figure 3
Ductoscopic cytology showing DCIS.International Seminars in Surgical Oncology 2006, 3:16 http://www.issoonline.com/content/3/1/16
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involving ductoscopy and the use of a blue dye to perform
microdochectomy [15,16]. MD can also potentially
reduce the need to perform duct excision in patients with
PND due to benign disease thus resulting in cost savings.
There are, however, recognised limitations to the use of
MD in clinical practice. The first limitation is related to the
breast anatomy. MD examines 1 – 2 ducts per breast and
leaves the remaining 13 – 18 ducts that open at or just
below the nipple surface unexamined. Although this
allows access to the main central ducts draining 75% of
the breast volume [17], it remains unknown whether
these ducts are the commonest sites of malignancy [2].
Currently, MD is incapable of reaching the peripheral
small branches of the ducts due to the scopes' diameter
[2,5,18]. Thus it is unable to visualise the terminal duct-
lobular unit (TDLU) where malignant lesions often origi-
nate. A recent report by Going et al. demonstrated the
complex architecture of the nipple-areolar complex and
the impending limitations of MD in the evaluation of the
ductal system. The three-dimensional model of the nipple
constructed by the authors revealed three distinct duct
populations some not accessible to MD or ductal lavage
[17]. The conclusion from this study is that accurate
knowledge of breast duct anatomy in three dimensions is
needed to understand the potential limitations of MD for
breast cancer screening.
Future development of new smaller calibre micro-endo-
scopes that can be maneuovered to more peripheral sites
may partially overcome this limitation [19].
The second limitation is related to histological verification
of endoscopic findings. Current biopsy tools need re-eval-
uation, as the challenge of verifying endoscopic appear-
ances with histological diagnosis has not yet been
overcome. The development of reliable intraductal biopsy
tools capable of obtaining tissue sample sufficient for his-
tological diagnosis has been hampered by the small diam-
eter of the working channels of the scopes. In addition,
ductal washings during MD retrieves only one third of the
fluid originally infused. Therefore, there is a considerable
fraction of fluid and cells that remain trapped, probably
within the smaller, more distally located ducts. Further-
more ductoscopic cytology frequently reveals atypia in
cases of papilloma [20].
Previous studies showed that cytology samples obtained
through MD-assisted ductal lavage is highly spicific, but it
lacks the required sensitivity to predict whether the breast
contains cancer [21,22]. Our study confirms that ductos-
copic cytology is not sufficiently sensitive for the diagno-
sis of malignancy and therefore we have developed an
intraductal biopsy device that obtains microbiopsies
under direct visualisation [19]. The limitations of cytology
can be also overcome by the development of novel tech-
nologies such as image analysis (IA), molecular diagnos-
tics and real-time optical biopsy [22,23]. The scoring
system for endoscopic appearances suggested earlier in
this study may help the dicision-making process in clini-
cal practice and aid communication between clinicians.
This proposed system requires future validation in large
studies correlating the macroscopic appearances of lesions
with their final histological diagnosis. It would aid, and
not substitute, histological examination, especially in
some cases where histology is not definitive.
Our study shows that MD is technically feasible in most
patients and has a potential in the early detection of breast
cancer. Furthermore, MD can complement other investi-
gations in diagnosing DCIS. In one patient in this study,
PND was associated with DCIS that was not detected by
mammography, ultrasound, discharge cytology, MRI or
galactography. The role of MD in guiding breast-conserv-
ing surgery (BCS) in some cases of DCIS has sparked some
controversy in the recent years. Dooley WC [24] used rou-
tine intra-operative MD during lumpectomy in 201
patients. Of the 201 patients (16 with atypical ductal
hyperplasia, 52 with ductal carcinoma-in-situ, and 133
with stage 1 or 2 breast cancers), 150 (74.6%) could be
successfully dilated and scoped. MD reduced the inci-
dence of positive margins from 23.5% to only 5.0%. The
author concluded that routine operative MD reduced the
need for re-excision surgery and found substantially more
cancerous and precancerous disease than anticipated by
routine preoperative mammography and ultrasound.
Conversely, Kim et al. [25] prospectively evaluated 30
patients undergoing therapeutic partial mastectomy for
in-situ and invasive breast carcinoma. Although the
number of patients in this trial was small, the authors con-
cluded that MD could identify intraductal abnormalities
during partial mastectomy in a significant number of
patients. Nevertheless, many of these findings were either
benign or within the standard field of resection, thus add-
ing no benefit to the patient. Therefore, randomized con-
trolled trials are needed to validate the hypothesis that
MD can guide breast-conserving surgery (BCS) and reduce
the need for re-excision procedures, especially in patients
with DCIS.
The above discussion also raises important questions
regarding the potential role of MD as a screening tool for
breast cancer. To date there has been no studies examining
the hypothesis that MD has a role in breast cancer screen-
ing. It is likely that MD will complement new evolving
screening modalities such as ductal lavage cytology using
microcatheters for screening and guiding risk-reducing
strategies in high-risk population [2,5,7]. There is an
apparent need for a large prospective clinical trial to eval-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
International Seminars in Surgical Oncology 2006, 3:16 http://www.issoonline.com/content/3/1/16
Page 7 of 7
(page number not for citation purposes)
uate the potential role of MD in the early detection of
breast cancer.
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